Covaxin is developed by Hyderabad-based Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology, Pune (NIV).
While official data shows 2.1 crore doses of Covaxin had been administered across the country till Thursday, based on statements from Bharat Biotech and Centre, at least 6 crore doses should have been produced and available for vaccination
Bharat Biotech agrees to open Covaxin manufacturing to others
Bharat Biotech has been producing Covaxin at its Biosafety Level-3 (BSL-3) facilities in Hyderabad and Bengaluru, where Production capacity had been enhanced in a step-wise manner
BusinessToday.In | May 13, 2021 | Updated 19:04 IST
Bharat Biotech has agreed to allow other companies to manufacture its coronavirus vaccine Covaxin, informed NITI Aayog Member (Health) Dr VK Paul. Addressing a press conference on the status of COVID-19 situation in the country on Thursday, Paul invited companies interested in joining the initiative to expand the production of Covaxin. People have asked that Covaxin be given to other companies for manufacturing. I am happy to say that Covaxin manufacturing company [Bharat Biotech] has welcomed this when we discussed it with them. Under this vaccine live virus is inactivated and this is done only in BSL3 labs, Paul said.
Covaxin efficacy of 81% testament to India s rise as global vaccine superpower: ICMR DG
The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR
Joe C Mathew | March 3, 2021 | Updated 19:42 IST
Indian Council of Medical Research (ICMR) has said that the interim efficacy results of Bharat Biotech s COVID-19 vaccine, Covaxin, showcases the immense strength of Atmanirbhar Bharat to fight the odds and stand tall in the global public health community.
The vaccine is the result of a partnership between ICMR and Bharat Biotech International Limited (BBIL).
Covaxin exceeds efficacy of most traditional platform-based COVID-19 vaccines
So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy
PB Jayakumar | March 3, 2021 | Updated 23:04 IST
With Bharat Biotech announcing 81 per cent interm efficacy for India s first indigeneously developed coronavirus vaccine Covaxin, India has joined the league of front runners across the globe who have developed the most efficient vaccines for this pandemic.
So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy. The Pfizer vaccine showed efficacy of 95 per cent at preventing symptomatic COVID infection after two doses and the Moderna vaccine is 94.1 per cent effective after the second dose. However, this vaccine s efficacy was seen slightly lower in people above 65 years. These vaccines are made usi